{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:16:33Z","timestamp":1759666593011},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.medcli.2020.02.005","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:43:56Z","timestamp":1589629436000},"page":"30-35","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagn\u00f3stico y tratamiento de la infecci\u00f3n por Clostridioides difficile"],"prefix":"10.1016","volume":"155","author":[{"given":"Lourdes","family":"Mateu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gema","family":"Fern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"Sopena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2020.02.005_bib0305","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/cid\/ciy149","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0310","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","article-title":"Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O\u2019Toole 1935) Pr\u00e9vot 1938","volume":"40","author":"Lawson","year":"2016","journal-title":"Anaerobe"},{"key":"10.1016\/j.medcli.2020.02.005_bib0315","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cmi.2018.01.027","article-title":"New insights into transmission of Clostridium difficile infection-narrative review","volume":"24","author":"Durovic","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0320","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update Update of the diagnostic guidance document for Clostridium difficile infection","volume":"22","author":"Crobach","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0140-6736(10)61266-4","article-title":"Clostridium difficile infection in Europe: a A hospital-based survey","volume":"377","author":"Bauer","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2020.02.005_bib0330","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1128\/CMR.00082-09","article-title":"The changing epidemiology of Clostridium difficile infections","volume":"23","author":"Freeman","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.medcli.2020.02.005_bib0335","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1017\/S0950268819001080","article-title":"Impact of a training program on the surveillance of Clostridioides difficile infection","volume":"147","author":"Sopena","year":"2019","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0340","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.medcli.2020.02.005_bib0345","series-title":"Diagn\u00f3stico microbiol\u00f3gico de la infecci\u00f3n por Clostridium difficile difficile","author":"Alcal\u00e1 Hern\u00e1ndez","year":"2015"},{"key":"10.1016\/j.medcli.2020.02.005_bib0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106118","article-title":"Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a A prospective cohort study","volume":"9","author":"Swale","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2020.02.005_bib0355","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1198-743x.2001.00294.x","article-title":"Laboratory diagnosis of Clostridium difficile disease","volume":"7","author":"Delm\u00e9ee","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.anaerobe.2012.12.001","article-title":"A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens","volume":"19","author":"Hink","year":"2013","journal-title":"Anaerobe"},{"key":"10.1016\/j.medcli.2020.02.005_bib0365","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1128\/jcm.9.2.214-219.1979","article-title":"Selective and differential medium for isolation of Clostridium difficile","volume":"9","author":"George","year":"1979","journal-title":"J. Clin. Microbiol"},{"key":"10.1016\/j.medcli.2020.02.005_bib0370","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/JCM.02601-12","article-title":"Evaluation of the Chromogenic Agar chromID C.difficile","volume":"51","author":"Eckert","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.medcli.2020.02.005_bib0375","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s15010-016-0940-9","article-title":"Rapid detection of Clostridium difficile toxins and laboratory diagnosis of Clostridium difficile infections","volume":"45","author":"Chen","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.medcli.2020.02.005_bib0380","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(14)70991-0","article-title":"Underdiagnosis of Clostridium difficile across Europe: The European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID)","volume":"14","author":"Davies","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41426-017-0019-4","article-title":"Advances in the diagnosis and treatment of Clostridium difficile infections","volume":"7","author":"Peng","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0390","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cmi.2018.02.026","article-title":"The pitfalls of laboratory diagnostics of Clostridium difficile infection","volume":"24","author":"Krutova","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0395","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cmi.2017.12.005","article-title":"How to: diagnose infection caused by Clostridium difficile","volume":"24","author":"Gateau","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0400","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1001\/jamainternmed.2015.4114","article-title":"Overdiagnosis of Clostridium difficile infection in the molecular test era","volume":"175","author":"Polage","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.medcli.2020.02.005_bib0405","doi-asserted-by":"crossref","first-page":"e98400","DOI":"10.1371\/journal.pone.0098400","article-title":"Risk factors for recurrence, complications and mortality in Clostridium difficile infection: A systematic review","volume":"9","author":"Abou Chakra","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2020.02.005_bib0410","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eimc.2012.12.010","article-title":"Infections caused by Clostridium difficile","volume":"31","author":"Rodr\u00edguez-Pardo","year":"2013","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.medcli.2020.02.005_bib0415","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0897190013515925","article-title":"Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile infection","volume":"28","author":"Bass","year":"2015","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.medcli.2020.02.005_bib0420","first-page":"347","article-title":"Long-term stability of vancomycin hydrochloride in oral solution: The brand name versus a generic product","volume":"20","author":"Huvelle","year":"2016","journal-title":"Int J Pharm Compd"},{"key":"10.1016\/j.medcli.2020.02.005_bib0425","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0430","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2020.02.005_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: Update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0440","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.02.005_bib0445","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2020.02.005_bib0450","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1093\/cid\/cis499","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection: Meta-analysis of pivotal randomized controlled trials","volume":"55","author":"Crook","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0455","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40273-017-0540-2","article-title":"A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection","volume":"35","author":"Burton","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.medcli.2020.02.005_bib0460","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciz318","article-title":"Cost-effectiveness of treatment regimens for Clostridioides difficile infection \u2014an evaluation of the 2018 Infectious Diseases Society of America guidelines","volume":"14","author":"Rajasingham","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0465","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/cid\/civ409","article-title":"The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with Clostridium difficile infection","volume":"61","author":"Rokas","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0470","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/SLA.0b013e31822ade48","article-title":"Diverting loop ileostomy and colonic lavage: An alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease","volume":"254","author":"Neal","year":"2011","journal-title":"Ann Surg"},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2020.02.005_bib0475","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1093\/cid\/cis462","article-title":"Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin","volume":"55","author":"Cornely","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0480","first-page":"111","article-title":"Extended duration vancomycin in recurrent Clostridium difficile infection: A systematic review","volume":"5","author":"Murphy","year":"2018","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0485","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","article-title":"Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): A randomised, controlled, open-label, phase 3b\/4 trial","volume":"18","author":"Guery","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0490","first-page":"854","article-title":"Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis","volume":"44","author":"Eiseman","year":"1958","journal-title":"Surgery"},{"key":"10.1016\/j.medcli.2020.02.005_bib0495","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"Van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.02.005_bib0500","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2020.02.005_bib0505","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/cid\/ciy721","article-title":"Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: A systematic review and meta-analysis","volume":"68","author":"Tariq","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0510","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciw731","article-title":"Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: An open-label randomized controlled trial","volume":"64","author":"Hota","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0515","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/apt.13492","article-title":"Systematic review with meta-analysis: Long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection","volume":"43","author":"Li","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.medcli.2020.02.005_bib0520","doi-asserted-by":"crossref","first-page":"e0161174","DOI":"10.1371\/journal.pone.0161174","article-title":"Systematic review: Adverse events of fecal microbiota transplantation","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.medcli.2020.02.005_bib0525","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.medcli.2020.02.005_bib0530","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2020.02.005_bib0535","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s12325-018-0813-y","article-title":"Cost-effectiveness analysis of bezlotoxumab added to standard of care versus standard of care alone for the prevention of recurrent Clostridium difficile infection in high-risk patients in Spain","volume":"35","author":"Salavert","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.medcli.2020.02.005_bib0540","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciy171","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection in patients at increased risk for recurrence","volume":"67","author":"Gerding","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0545","doi-asserted-by":"crossref","first-page":"l4609","DOI":"10.1136\/bmj.l4609","article-title":"Clostridioides difficile: Diagnosis and treatments","volume":"366","author":"Guery","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.medcli.2020.02.005_bib0550","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmi.2016.08.017","article-title":"Use of intravenous tigecycline in patients with severe Clostridium difficile infection: A retrospective observational cohort study","volume":"22","author":"Gergely Szabo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medcli.2020.02.005_bib0555","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/imj.13742","article-title":"The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: A retrospective observational study","volume":"48","author":"Bishop","year":"2018","journal-title":"Intern Med J"},{"key":"10.1016\/j.medcli.2020.02.005_bib0560","article-title":"Ridinilazole for Clostridium difficile infections: Safety and efficacy compared with vancomycin from the CoDIFy Phase 2 Trial","author":"Vickers","year":"2016","journal-title":"Amsterdam: Eur Congr Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0565","first-page":"18","article-title":"Do prophylactic probiotics prevent the incidence of Clostridium difficile colitis infection in hospitalized patients?","volume":"112","author":"Rodriguez","year":"2019","journal-title":"J Okla State Med Assoc"},{"key":"10.1016\/j.medcli.2020.02.005_bib0570","first-page":"CD006095","article-title":"Probiotics for the prevention of Clostridium difficile associated diarrhea in adults and children","volume":"12","author":"Goldenberg Joshua","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2020.02.005_bib0575","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1053\/j.gastro.2017.02.003","article-title":"Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: A systematic review with meta-regression analysis","volume":"152","author":"Shen","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2020.02.005_bib0580","article-title":"Management of Clostridioides difficile colitis: Insights for the gastroenterologist","volume":"6","author":"Saha","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.medcli.2020.02.005_bib0585","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.medcli.2020.02.005_bib0590","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medcli.2020.02.005_bib0595","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/jac\/dkr377","article-title":"A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhea in patients with Clostridium difficile infection","volume":"66","author":"Garey","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medcli.2020.02.005_bib0600","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gutjnl-2018-316794","article-title":"Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): A randomized placebo controlled trial","volume":"68","author":"Major","year":"2019","journal-title":"Gut"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532030172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532030172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:43:53Z","timestamp":1696139033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577532030172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S002577532030172X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2020.02.005","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagn\u00f3stico y tratamiento de la infecci\u00f3n por Clostridioides difficile","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2020.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}